Connect Biopharma presented clinical data on rademikibart, its investigational IL-4Rα antibody for asthma and COPD, at the 2025 EAACI Annual Congress. The data showed rademikibart significantly improved lung function and reduced annualized exacerbation rates in patients with eosinophilic-driven type 2 asthma. This research supports ongoing Phase 2 studies in asthma and COPD, with topline data expected in the first half of 2026.
These findings are potentially crucial for advancing asthma and COPD treatment. Rademikibart’s rapid improvement in lung function, observed as early as one week into treatment, distinguishes it from current therapies. The significant reduction in annualized exacerbation rates, especially in patients with high eosinophil and FeNO counts, suggests rademikibart could effectively target type 2 inflammation, a key driver of these conditions. This targeted approach could lead to better disease management and improved quality of life for patients.
Post-hoc analysis of the Phase 2b asthma trial revealed that rademikibart improved prebronchodilator FEV1 at week one, sustained through 24 weeks. Improvements were more pronounced in subgroups with elevated baseline eosinophil counts. The drug also led to better patient-reported asthma control and fewer instances of high post-baseline eosinophil counts compared to dupilumab. Furthermore, rademikibart achieved clinically meaningful reductions in annualized asthma exacerbation rates: 63% in patients with elevated eosinophils, 69% with elevated FeNO, and 74% with both.
The positive data from the Phase 2b trial strengthens the rationale for the ongoing Phase 2 acute exacerbation studies in asthma and COPD. If the upcoming trials confirm these findings, rademikibart could represent a significant advancement in respiratory disease management, offering a new treatment option with rapid onset and sustained efficacy for patients with eosinophilic-driven type 2 asthma and potentially COPD. This could lead to a shift in treatment paradigms and potentially improve outcomes for a large population of patients experiencing exacerbations.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
